Table 1. Demographic data and basic CSF findings of patients included in this study.
| ALS | PD | CTRL | S | |||
| Fast | Slow | |||||
| n (female/male) | 68 (30/38) | 34 (16/18) | 34 (14/20) | 20 (10/10) | 40 (20/20) | |
| Median (Range) | ||||||
| Age | 65 (33–84) | 67 (33–84) | 63 (39–74) | 69 (44–86) | 62 (21–71) | NS |
| Duration of disease [months] | 15 (6–67) | 18 (6–67) | 16 (6–58) | 72 (6–300) | NS* | |
| MRCS | 56 (33–60) | 54 (40–60) | 58 (38–60) | |||
| ΔMRCS | 0.9 (0–9) | 2 (0.9–9) | 0.2 (0–0.9) | |||
| ALSFRS–R | 40 (6–48) | 41 (6–46) | 40 (21–48) | |||
| CSF cell count [cells/µL] | 1 (0–4) | 1 (0–4) | 1 (0–4) | 1 (0–2) | 1 (0–4) | NS |
| Qalb (x 0.001) | 6.4 (2.3–14.2) | 6.6 (2.3–12.4) | 5.5 (2.9–14.2) | 6.0 (2.8–16.5) | 5.4 (2.7–10.6) | NS |
*across subgroups of ALS.
ALSFRS-R = revised Amyotrophic Lateral Sclerosis Functional Rating Scale, CTRL = controls, fast = ALS patients with fast progression of disease over follow-up, MRCS = Medical Research Council Sumscore, ΔMRCS = change in MRC score/time, NS = not significant, PD = Parkinson's disease, Qalb = albumin CSF/serum quotient, slow = ALS patients with slow progression of disease over follow-up, S = Significance in Kruskal-Wallis One Way Analysis of Variance on Ranks.